This brand name is authorized in Australia, Austria, France, Hong Kong SAR China, Poland, Spain, Turkey, UK.
The drug TEGLUTIK contains one active pharmaceutical ingredient (API):
1
|
UNII
7LJ087RS6F - RILUZOLE
|
|
Riluzole is proposed to act by inhibiting glutamate processes. The mode of action is unclear. It is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the ALS disease. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N07XX02 | Riluzole | N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 11662T |
| ES | Centro de información online de medicamentos de la AEMPS | 78243 |
| FR | Base de données publique des médicaments | 68413596 |
| GB | Medicines & Healthcare Products Regulatory Agency | 308405 |
| HK | Department of Health Drug Office | 67243 |
| PL | Rejestru Produktów Leczniczych | 100340388 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699324650064 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.